Materials and methods for evaluating and treating neuromyelitis optica (nmo)

Abstract

The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases.

1 . (canceled) 
     
     
         2 . A method of treating an individual that has a disorder related to aquaporin-4 (AQP4) autoimmunity, said method comprising administering an anti-05 antibody to an individual identified as being serologically positive for AQP4-IgG autoantibody. 
     
     
         3 . The method of  claim 2 , wherein said disorder is neuromyelitis optica (NMO) or an NMO-associated disease. 
     
     
         4 . The method of  claim 2 , wherein said anti-05 antibody is administered orally. 
     
     
         5 . The method of  claim 2 , further comprising administering a glutamate receptor antagonist. 
     
     
         6 . The method of  claim 5 , wherein said glutamate receptor antagonist is selected from the group consisting of 1-amino-3,5-dimethyl-adamantane, 1-aminoadamantane, (+)-3-methoxy-17-methyl-(9α,13α,14α)-morphinan, 17-methyl-9a,13a,14a-morphinan-3-ol, 2-(2-chlorophenyl)-2-methylamino-cyclohexan-1-one, 1-(1-phenylcyclohexyl)piperidine, (±)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride, and 6-(Dimethylamino)-4,4-diphenylheptan-3-one. 
     
     
         7 . The method of  claim 5 , wherein said glutamate receptor antagonist is 1-amino-3,5-dimethyl-adamantane, 1-aminoadamantane. 
     
     
         8 . The method of  claim 2 , further comprising monitoring the individual for a decrease in the severity of said disorder. 
     
     
         9 . A method of treating an individual that has a disorder related to AQP4 autoimmunity, said method comprising:
 (a) identifying an individual as being serologically positive for AQP4-IgG autoantibody; and   (b) administering an anti-05 antibody to the individual.   
     
     
         10 . The method of  claim 9 , wherein said disorder is NMO or an NMO-associated disease. 
     
     
         11 . The method of  claim 9 , wherein said anti-05 antibody is administered orally. 
     
     
         12 . The method of  claim 9 , further comprising administering a glutamate receptor antagonist. 
     
     
         13 . The method of  claim 12 , wherein said glutamate receptor antagonist is selected from the group consisting of 1-amino-3,5-dimethyl-adamantane, 1-aminoadamantane, (+)-3-methoxy-17-methyl-(9α,13α,14α)-morphinan, 17-methyl-9a,13a,14a-morphinan-3-ol, 2-(2-chlorophenyl)-2-methylamino-cyclohexan-1-one, 1-(1-phenylcyclohexyl)piperidine, (±)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride, and 6-(Dimethylamino)-4,4-diphenylheptan-3-one. 
     
     
         14 . The method of  claim 13 , wherein said glutamate receptor antagonist is 1-amino-3,5-dimethyl-adamantane, 1-aminoadamantane. 
     
     
         15 . The method of  claim 9 , further comprising monitoring the individual for a decrease in the severity of said disorder.